Visceral fat, the primary driver of obesity-related cardiovascular risk, begins declining within weeks of starting treatment
Non-pharmacological management is equally important and should include physiotherapy, occupational therapy, and patient education programmes
Broad Application in Cardiovascular Concerns: Major Potential In 2025, crucial research activities will be developing new applications of GLP-1 receptor agonists in heart conditions, including protective effects on the heart and blood vessels, probably decreasing the risk of heart attack, stroke, and other cardiovascular events
This is because semaglutide also slows the emptying of your stomach and suppresses your appetite but is less likely to cause the same results as Wegovy as it comes in a lower dose for blood sugar management
Pills can help with appetite or fat absorption, but they are not a shortcut
Physicians may prescribe FDA-approved or compounded medications based on patient needs and clinical necessity